Close Menu

Biocept

Excluding the impact of a one-time conversion from cash-based to accrual-based revenue recognition in 2017, year-over-year revenues were essentially flat.

The company saw a drop in its Q4 sample accessions compared to the same quarter last year, but posted increases in both testing and revenues for the full year.

After validating Thermo Fisher's Oncomine panels in Biocept's CLIA lab, the companies plan to offer liquid biopsy testing to the pharmaceutical industry.

The firm plans to use the $13.3 million in net proceeds to fund ongoing operations, expansions of its liquid biopsy business, and to service its indebtedness.

The company plans to use proceeds to support its ongoing operations, expansion of its business, and to service existing debts.

This is Biocept's third BCBS contract and enables cancer patients to access the company's testing services in network under their Wellmark health plans.

Net proceeds from the offering of more than 4.9 million shares will be used for working capital and other general corporate purposes.  

The trial aims to demonstrate the utility of Biocept's Target Selector PD-L1 assay in patients diagnosed with non-small cell lung cancer.

The company had $1.1 million in revenue during the quarter, a 10 percent increase year over year despite what the firm said was a 15 to 20 percent sales reduction due to recent hurricanes.

The Target Selector technology is designed to analyze both circulating tumor cell and circulating tumor DNA biomarkers from a blood sample.

Pages

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.

LiveScience reports that a novel mutation in the LPL gene was uncovered in three siblings with very high triglyceride levels.

The president of Nankai University is embroiled in a data manipulation scandal, the South China Morning Post reports.

In PNAS this week: cytotoxic CD4 T cell signature in supercentenarians, evolutionary history of beetles, and more.